Lexaria Bioscience (LEXX) Updates Current GLP-1 Market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Lexaria Updates Current GLP-1 Market
October 8, 2024 9:20 AM EDTKelowna, British Columbia, Oct 8, 2024 - (NewMediaWire) - - Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements.
In 2020 the total market size for GLP-1 drugs was less than $4 billion. That same year, Novo Nordisk(R) paid $1.8 billion to purchase Emisphere's(R) SNAC drug delivery technology which was subsequently incorporated into Rybelsus(R) semaglutide oral tablets, resulting in the first and only Food and Drug Administration ("FDA") approved GLP-1 drug for use as an oral tablet.
Today,... More
